泰格医药, Tigermed ,   
杭州泰格医药科技股份有限公司是国内领先的临床合同研究组织（CRO），专注于为医药产品研发提供I-IV期临床试验、数据管理与生物统计、注册申报等全方位服务。公司自成立以来，一直致力于为客户提供高质量和高效率的医药研发服务，帮助客户降低研发风险、节约研发经费，推进产品市场化进程。

公司总部位于杭州，下设七家子公司，构筑了涵盖临床研究产业链各个环节的完整服务体系。截止2011年底，在国内40多个主要城市设有办事机构，拥有近600人的国际化专业团队，建立了国际标准的操作规程（SOP）。泰格医药已经为国内外300多家客户成功提供了近千项临床试验、注册申报、数据管理和生物统计服务。因为拥有33种创新药（包括23种新化学单体和10个新生物制品）的临床研究经验与成就，泰格医药是国内领先的“创新型CRO”。

Hangzhou Tigermed Consulting Co., Ltd is a leading Contract Research Organization (CRO) in China dedicated to providing regulatory affairs, Phase I-IV clinical trials, data management, biostatistics, medical translation and GCP training services for healthcare products. Since inception in 2004, Tigermed has been committed to accelerating your product development timeline while reducing R&D costs and risks, helping you to bring the miracles of your new product to market effectively.

Headquartered in Hangzhou, Tigermed operates 7 subsidiaries, 40 offices in China mainland. With more than 600 staff, Tigermed has set up global Standard Operating Procedures (SOPs) and successfully serviced more than 300 local and global clients in the conduct of hundreds of regulatory affairs, clinical trials, data management and biostatistics projects. Through our unmatched experience and outstanding achievements in the development of 33 innovative drugs (23 NCEs and 10 new biological products), Tigermed is recognized as “An Innovative CRO” in China.